Leslie Cho, MD
, and Jennifer G. Robinson, MD, MPH
, provide their perspectives on issues related to the evolving role and value of PCSK9 inhibitors in the management of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. Drs. Cho and Robinson examine the impact of PCSK9 inhibitors on patients with elevated low-density lipoprotein cholesterol (LDL-C) and apolipoprotein B, including the benefits and risks of lowering LDL-C below 25 mg/dL. They discuss the evidence regarding possible effects of PCSK9 inhibitors on cognition and antibody formation. Suggestions are offered for overcoming restrictions to PCSK9 inhibitor therapy implemented by payers.
- Proprotein convertase subtilisin-kexin type 9 inhibitors
- Low-density lipoprotein cholesterol hypercholesterolemia
- Apolipoprotein B
- Overcoming payer restrictions
This activity was developed for cardiologists, cardiology fellows, nurses, nurse practitioners, physician assistants, pharmacists and other health care professionals who have an interest in lipid management.
This activity is supported by educational funding provided by Amgen.
Leslie Cho, MD
Director, Women's Cardiovascular Center; Section Head
Preventive Cardiology and Rehabilitation, Cleveland Clinic
Jennifer G. Robinson, MD, MPH
Professor, Departments of Epidemiology, and Medicine (Division of Cardiology)
Director, Prevention Intervention Center
College of Public Health
University of Iowa
Iowa City, Iowa